Jeff E. Knight has sold CRNX and made no open-market buys since Mar 2024

Jeff E. Knight, M.P.H., is a seasoned biopharmaceutical executive with over 30 years of experience in clinical development, portfolio strategy, program management, and operations.( He joined Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) in September 2021 as Chief Operating Officer, later advancing to Chief Development & Operating Officer, where he oversaw strategic operations, including program and portfolio management, alliance management, IT, facilities, clinical development, and corporate operations.( Prior to Crinetics, Knight served on the executive leadership team at Poseida Therapeutics, managing portfolio strategy, alliances, quality, compliance, and operations; held escalating roles in clinical, development, and corporate operations at Amgen, Onyx Pharmaceuticals (Amgen subsidiary), and Halozyme Therapeutics (2012-2018); and earlier gained expertise in clinical development, program management, and regulatory affairs at Genentech, Hoechst Marion Roussel (now Sanofi), and PRA International.(

Knight holds a Bachelor of Science in Nursing from the University of Kansas, a Bachelor of Arts in Psychology, and a Master of Public Health in Biostatistics and Epidemiology from the University of Oklahoma.( As of April 2026, he owned approximately 105,289 shares of CRNX stock valued at $4 million and had recently engaged in insider trading activities.( On April 13, 2026, he was appointed Chief Development and Operating Officer at ALX Oncology Holdings Inc. (Nasdaq: ALXO).(

Written by Perplexity from public sources.